Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
Decision snapshot: LGND stock price vs PHG: inconclusive Relative valuation is incomplete for this pair. Review the available filing metrics before drawing a conclusion.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at PHG's multiple
Needs PHG P/E.
Implied fair value · at LGND's multiple
Needs LGND P/E.
Snapshot Sep 4, 4:00 PM ET
Metric by metric
Where each company leads, and how wide the gap is.
Growth edge
Pricing power
Operating leverage
Multiple premium
Not comparable
Lower leverage
Statements
Core statements aligned to each company's latest fiscal year.
SEC periods: LGND FY 2025 (ended Dec 31, 2025) · PHG FY 2025 (ended Dec 31, 2025).
Trendline
Five fiscal years of revenue, earnings, and margins before underwriting a re-rating.
Price framework
Market cap plus debt, less cash.
Capital structure 94% equity / 6% debt · EV / Revenue 19.90x · EV / EBITDA 33.28x
Capital structure 61% equity / 39% debt · EV / Revenue 1.94x · EV / EBITDA 29.13x
PHG carries the larger enterprise value at $40.12B against $5.33B; PHG trades on the lower EV / Revenue multiple (1.94x vs 19.90x); PHG on the lower EV / EBITDA (29.13x vs 33.28x).
Price framework
The same filing-backed model used on each company's valuation page, with company-specific inputs and calculated scenarios.
LIGAND PHARMACEUTICALS INCORPORATED · implied price per share
Debt and bridge-cash inputs are required to translate enterprise value into equity value.
KONINKLIJKE PHILIPS NV · implied price per share
Five annual free-cash-flow observations are required for the filing-backed baseline.
Balance sheet health
Financial health checks to separate durable balance sheets from potential value traps.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Debt / equity
Total debt against shareholders' equity
0.37x
—
Net debt / EBITDA
Leverage against operating earnings
-2.24x
11.03x
Cash and equivalents
Liquid reserves on the balance sheet
$733.52M
$2.79B
Total debt
Interest-bearing obligations outstanding
$374.08M
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
Royalty Pharma plc
LGND vs RPRX
Sarepta Therapeutics, Inc.
LGND vs SRPT
INCYTE CORP
LGND vs INCY
EXELIXIS, INC.
LGND vs EXEL
GE HealthCare Technologies Inc.
LGND vs GEHC
HOLOGIC INC
LGND vs HOLX
BOSTON SCIENTIFIC CORP
LGND vs BSX
INTUITIVE SURGICAL INC
LGND vs ISRG
ZIMMER BIOMET HOLDINGS, INC.
LGND vs ZBH
$15.86B
LLM-powered synthesis
An on-demand narrative read of the same deterministic data.
This explanation uses an earlier data snapshot or evidence version. Review its generation date and the current figures, or refresh after signing in.
If you believe LGND can sustain its 60.4% revenue growth and 46.4% net margin, then hold or accumulate selectively despite the valuation premium, because the business quality is clearly better than PHG’s; otherwise, the P/E and DCF gaps suggest LGND is overextended and vulnerable to multiple compression.
On a P/E basis, LGND’s current price of $319.55 sits well above the implied price of $158.02, implying a -50.5% downside under that framework. The gap is driven by LGND’s much higher absolute multiples versus PHG, even though LGND also deserves some premium for superior growth and profitability.
Supporting Metrics
